---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-018761"
form_type: "8-K"
ticker: "RTGN"
cik: "0001836295"
company_name: "RetinalGenix Technologies Inc."
filed_at: "2022-07-07T23:59:59+00:00"
generated_at: "2026-06-24T19:57:21.494625+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# RetinalGenix acquires DNA/GPS for 2M shares; combines retinal imaging with genetic mapping

## Summary
- Acquired all outstanding shares of DNA/GPS Inc. in exchange for 2,000,000 shares of RTGN common stock.
- DNA/GPS is a pharmacogenetics company based in Tampa, FL, founded by Dr. Lawrence Perich.
- Combined platform aims to enable home-based screening and diagnosis of systemic diseases like heart disease, Alzheimer's, Parkinson's.
- Dr. Perich to join advisory board; platform expected to reduce reliance on costly procedures like CT, MRI, PET.
- Shares issued in private placement exempt from registration under Section 4(a)(2).

## SEC filing metadata
- accession: 0001493152-22-018761
- form_type: 8-K
- ticker: RTGN
- cik: 0001836295
- company_name: RetinalGenix Technologies Inc.
- filed_at: 2022-07-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1836295/000149315222018761/0001493152-22-018761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1836295/000149315222018761/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-018761
- JSON: https://secwatch.observer/filing/0001493152-22-018761.json
- Plain text: https://secwatch.observer/filing/0001493152-22-018761.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.